Biologics Rare and Orphan Care™ has proven expertise in the successful commercialization of rare disease therapies with clinical-stage manufacturers. Our experienced and agile specialty pharmacy implementation team brings a deep understanding of patient care needs and market dynamics to every product launch. We help our biopharma partners develop innovative, customized solutions and therapy-specific launch strategies to deliver exceptional results.

With hyper-focused, personalized care at the very core of what we do, Biologics can manage the complex corners of the rare disease industry. We know the challenges our patients face, as well as our stakeholders, are complex and our three decades of clinical expertise in the specialty pharmacy market prove that we are a stable partner. While backed by McKesson at an enterprise level, we remain nimble and independent, allowing us to remain committed to our biopharma counterparts and planted in our core mission of focusing on each of our patients and their therapeutic journey.

• 30 years of expertise in delivering solutions for highly complex, orphan-designated therapies
• Proud to offer 19 exclusive therapies
• Launch partner for 17 rare and ultra rare therapies
• Extensive expertise in the rare areas of nephrology, rare oncology like TGCT, Polycytemia Vera, and much more.
• 115 active limited distribution drugs (LDD)
• 40+ 1 of 3 or fewer specialty pharmacy provider (SPP) LDD contracts
• 10 integrated HUB programs
• 70+ clinicians
• Robust licensing in 50 U.S. states and territories

Built on the foundation of deep clinical expertise and a high-touch approach to patient care, our strategic solutions for your orphan drug deliver seamless access and deep engagement.

As finding treatment options for these populations has become a priority, so too has the need for biopharma companies to identify and partner with specialty pharmacy providers that can serve the niche needs of their rare disease population with agility. However, the journey from clinical development to market access presents distinctive challenges. As biopharma begins to shift from clinical development and regulatory functions to their commercial planning, they must leverage their specialty pharmacy partners for commercial expertise residing within their selected partners.

Drug manufacturers are seeking smooth commercialization paths in parallel with simplified treatment journeys for their patients. Their launch strategists and market access experts are always weighing the commercialization strategies against ease of access to unlock the full potential of their launch.

The support a biopharma company gets from an experienced specialty pharmacy is critical to the success of its drug in the marketplace. An effective launch enables the company to provide appropriate solutions to unmet needs and place patients at the forefront of its commercialization strategy. This engagement—even in the early stages of commercial planning—ultimately powers the success of the brand. As more therapies become available for previously untreatable conditions, companies are seeking smooth commercialization paths in parallel with simplified treatment journeys for their patients.

Along with our clinical expertise, each of our Biologics Biopharma partners receives comprehensive solutions from our integrated, multi-disciplinary team to support the critical parts of their programs including:

• Access & adherence
• Business intelligence, data, analytics
• Cell & gene strategies
• Clinical & expanded access protocols & innovation
• Copay solutions
• Nursing support
• Patient assistance programs
• Operational excellence
• Risk evaluation & mitigation strategies (REMS)
• Therapy education

Contact us to learn how we can support your rare and orphan therapy launch.